Expansion of a Pharmacokinetic Model for Diazepam to Characterize Real‐World IV and Oral Data in Children With and Without Obesity
Sean McCann(University of North Carolina at Chapel Hill), Daniel González(University of North Carolina at Chapel Hill), Chi D. Hornik, Sarah G. Anderson(Emmes (United States)), Jiali Wen(University of North Carolina at Chapel Hill), William J. Muller(Lurie Children's Hospital), Amira Al‐Uzri(Oregon Health & Science University), James M. Chamberlain(George Washington University Hospital), Sitora Turdalieva(Emmes (United States)), Stephen J. Balevic(Duke University), Elizabeth H. Payne(Emmes (United States)), Marisa Meyer(Nemours Children's Health System)
Cited by 1
Related Papers
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
|Journal of Pharmaceutical Sciences|2009|337
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
|Clinical Infectious Diseases|2020|232
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
|Clinical Infectious Diseases|2022|201